{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-080022","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2024-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.261684+00:00","generated_at":"2026-05-31T20:31:23.165627+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioXcel reports preliminary Q2 2024 IGALMI net revenue of $1.1M, up 90% QoQ","bullets":["Preliminary Q2 2024 net revenue from IGALMI approximately $1.1M, up 90% from Q1 2024 and 141% from Q2 2023.","Growth driven by increased contracting with psychiatric clinics and behavioral health facilities via small commercial team.","CEO cites potential for at-home expansion if BXCL501 approved, targeting estimated 23M annual agitation episodes.","Full Q2 2024 financial results and business update to be discussed on a future earnings call (date TBD)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-080022","json":"https://secwatch.observer/filing/0001104659-24-080022.json","markdown":"https://secwatch.observer/filing/0001104659-24-080022.md","text":"https://secwatch.observer/filing/0001104659-24-080022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924080022/0001104659-24-080022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924080022/tm2419377d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:31:23.165627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}